Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -20.41M | -21.37M | -21.60M | -21.14M | -22.27M |
| Total Depreciation and Amortization | 37.00K | 39.30K | 37.20K | 37.80K | 37.50K |
| Total Amortization of Deferred Charges | 47.00K | 47.00K | 48.00K | 47.00K | 46.00K |
| Total Other Non-Cash Items | 2.53M | 2.04M | 2.46M | 2.42M | 2.88M |
| Change in Net Operating Assets | -1.08M | -1.84M | 81.50K | 401.50K | 442.20K |
| Cash from Operations | -18.87M | -21.08M | -18.97M | -18.24M | -18.87M |
| Capital Expenditure | -22.40K | -21.50K | -22.20K | -4.30K | -15.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.00M | 8.18M | 10.11M | 11.14M | 10.24M |
| Cash from Investing | 4.98M | 8.16M | 10.09M | 11.13M | 10.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -90.90K | -90.70K | -90.20K | -90.30K | -89.00K |
| Issuance of Common Stock | 13.38M | 20.63M | 19.96M | 12.12M | 12.73M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -280.90K | -280.90K | -280.90K | -280.90K | -- |
| Cash from Financing | 13.01M | 20.26M | 19.59M | 11.75M | 12.64M |
| Foreign Exchange rate Adjustments | -527.20K | 436.60K | -90.80K | 7.40K | 488.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.41M | 7.78M | 10.62M | 4.65M | 4.49M |